Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

Compare

726 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MIRM Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Mirum

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MIRM Stock 12 Month Forecast

Average Price Target

$105.90

▲(16.31% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $105.90 with a high forecast of $140.00 and a low forecast of $94.00. The average price target represents a 16.31% change from the last price of $91.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"$40","141":"$141","65.25":"$65.3","90.5":"$90.5","115.75":"$115.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$105.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$94.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,65.25,90.5,115.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.99,83.68307692307692,88.37615384615384,93.06923076923077,97.76230769230769,102.45538461538462,107.14846153846153,111.84153846153846,116.53461538461539,121.22769230769231,125.92076923076922,130.61384615384617,135.30692307692308,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.99,81.06,83.13,85.2,87.27,89.34,91.41,93.48,95.55,97.62,99.69,101.76,103.83000000000001,{"y":105.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.99,80.14461538461538,81.29923076923076,82.45384615384614,83.60846153846154,84.76307692307692,85.9176923076923,87.07230769230769,88.22692307692307,89.38153846153845,90.53615384615384,91.69076923076923,92.84538461538462,{"y":94,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$140.00

Average Price Target$105.90

Lowest Price Target$94.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Swayampakula Ramakanth

H.C. Wainwright

$81→$102

Buy

12.03%

Upside

Reiterated

01/13/26

Mirum Pharmaceuticals price target raised to $102 from $81 at H.C. WainwrightMirum Pharmaceuticals price target raised to $102 from $81 at H.C. Wainwright

Ryan Deschner

Raymond James

$89.31→$110

Buy

20.81%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), Mirum Pharmaceuticals (NASDAQ: MIRM) and United Therapeutics (NASDAQ: UTHR)

Joseph Thome

TD Cowen

$95

Buy

4.34%

Upside

Reiterated

01/12/26

TD Cowen Remains a Buy on Mirum Pharmaceuticals (MIRM)

Brian Skorney

Robert W. Baird

$88→$95

Buy

4.34%

Upside

Reiterated

01/12/26

Mirum Pharmaceuticals price target raised to $95 from $88 at BairdMirum Pharmaceuticals price target raised to $95 from $88 at Baird

Jonathan Wolleben

Citizens JMP

$95→$140

Buy

53.76%

Upside

Reiterated

12/19/25

Mirum Pharmaceuticals price target raised to $140 from $95 at CitizensMirum Pharmaceuticals price target raised to $140 from $95 at Citizens

Gavin Clark-Gartner

Evercore ISI

$94

Buy

3.24%

Upside

Reiterated

12/17/25

Evercore ISI Keeps Their Buy Rating on Mirum Pharmaceuticals (MIRM)

James Condulis

Stifel Nicolaus

$92→$98

Buy

7.63%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Novan (NASDAQ: NOVN) and Argenx Se (NASDAQ: ARGX)

Mani Foroohar

Leerink Partners

$90→$100

Buy

9.83%

Upside

Reiterated

12/10/25

Mirum Pharmaceuticals price target raised to $100 from $90 at LeerinkMirum Pharmaceuticals price target raised to $100 from $90 at Leerink

Michael Ulz

Morgan Stanley

$81→$95

Buy

4.34%

Upside

Reiterated

12/09/25

Analysts' Top Healthcare Picks: Mirum Pharmaceuticals (MIRM), Eli Lilly & Co (LLY)

Joshua Schimmer

Cantor Fitzgerald

$95→$130

Buy

42.78%

Upside

Reiterated

12/08/25

Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor FitzgeraldMirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald

Jessica Fye

J.P. Morgan

$53→$77

Buy

-15.43%

Downside

Reiterated

09/12/25

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorganMirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan

David Lebowitz

Citi

$89

Buy

-2.25%

Downside

Reiterated

08/18/25

Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)

Ed Arce

Westpark Capital

$66→$72

Buy

-20.92%

Downside

Reiterated

02/27/25

Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Swayampakula Ramakanth

H.C. Wainwright

$81→$102

Buy

12.03%

Upside

Reiterated

01/13/26

Mirum Pharmaceuticals price target raised to $102 from $81 at H.C. WainwrightMirum Pharmaceuticals price target raised to $102 from $81 at H.C. Wainwright

Ryan Deschner

Raymond James

$89.31→$110

Buy

20.81%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), Mirum Pharmaceuticals (NASDAQ: MIRM) and United Therapeutics (NASDAQ: UTHR)

Joseph Thome

TD Cowen

$95

Buy

4.34%

Upside

Reiterated

01/12/26

TD Cowen Remains a Buy on Mirum Pharmaceuticals (MIRM)

Brian Skorney

Robert W. Baird

$88→$95

Buy

4.34%

Upside

Reiterated

01/12/26

Mirum Pharmaceuticals price target raised to $95 from $88 at BairdMirum Pharmaceuticals price target raised to $95 from $88 at Baird

Jonathan Wolleben

Citizens JMP

$95→$140

Buy

53.76%

Upside

Reiterated

12/19/25

Mirum Pharmaceuticals price target raised to $140 from $95 at CitizensMirum Pharmaceuticals price target raised to $140 from $95 at Citizens

Gavin Clark-Gartner

Evercore ISI

$94

Buy

3.24%

Upside

Reiterated

12/17/25

Evercore ISI Keeps Their Buy Rating on Mirum Pharmaceuticals (MIRM)

James Condulis

Stifel Nicolaus

$92→$98

Buy

7.63%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Novan (NASDAQ: NOVN) and Argenx Se (NASDAQ: ARGX)

Mani Foroohar

Leerink Partners

$90→$100

Buy

9.83%

Upside

Reiterated

12/10/25

Mirum Pharmaceuticals price target raised to $100 from $90 at LeerinkMirum Pharmaceuticals price target raised to $100 from $90 at Leerink

Michael Ulz

Morgan Stanley

$81→$95

Buy

4.34%

Upside

Reiterated

12/09/25

Analysts' Top Healthcare Picks: Mirum Pharmaceuticals (MIRM), Eli Lilly & Co (LLY)

Joshua Schimmer

Cantor Fitzgerald

$95→$130

Buy

42.78%

Upside

Reiterated

12/08/25

Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor FitzgeraldMirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald

Jessica Fye

J.P. Morgan

$53→$77

Buy

-15.43%

Downside

Reiterated

09/12/25

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorganMirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan

David Lebowitz

Citi

$89

Buy

-2.25%

Downside

Reiterated

08/18/25

Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)

Ed Arce

Westpark Capital

$66→$72

Buy

-20.92%

Downside

Reiterated

02/27/25

Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

3 Months

xxx

Success Rate

21/32 ratings generated profit

Average Return

+10.59%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.63% of your transactions generating a profit, with an average return of +10.59% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

20/20 ratings generated profit

Average Return

+53.95%

reiterated a buy rating last month

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +53.95% per trade.

2 Years

xxx

Success Rate

18/18 ratings generated profit

Average Return

+126.06%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +126.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIRM Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MIRM has received 24 Buy Ratings, 21 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 105.90.

Each month's total comprises the sum of three months' worth of ratings.

MIRM Financial Forecast

MIRM Earnings Forecast

Next quarter’s earnings estimate for MIRM is >-$0.01 with a range of -$0.26 to $0.21. The previous quarter’s EPS was $0.05. MIRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Sales Forecast

Next quarter’s sales forecast for MIRM is $140.17M with a range of $131.00M to $148.66M. The previous quarter’s sales results were $133.01M. MIRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Stock Forecast FAQ

What is MIRM’s average 12-month price target, according to analysts?

Based on analyst ratings, Mirum Pharmaceuticals Inc’s 12-month average price target is 105.90.

What is MIRM’s upside potential, based on the analysts’ average price target?

Mirum Pharmaceuticals Inc has 16.31% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MIRM a Buy, Sell or Hold?

Mirum Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mirum Pharmaceuticals Inc’s price target?

The average price target for Mirum Pharmaceuticals Inc is 105.90. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $94.00. The average price target represents 16.31% Increase from the current price of $91.05.

What do analysts say about Mirum Pharmaceuticals Inc?

Mirum Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of MIRM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

MIRM Analyst Ratings

MIRM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mirum Pharmaceuticals

MIRM Analyst Recommendation Trends

MIRM Financial Forecast

MIRM Earnings Forecast

MIRM Sales Forecast

MIRM Stock Forecast FAQ

Detailed List of Analyst Forecasts